JP2020518248A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020518248A5 JP2020518248A5 JP2019560083A JP2019560083A JP2020518248A5 JP 2020518248 A5 JP2020518248 A5 JP 2020518248A5 JP 2019560083 A JP2019560083 A JP 2019560083A JP 2019560083 A JP2019560083 A JP 2019560083A JP 2020518248 A5 JP2020518248 A5 JP 2020518248A5
- Authority
- JP
- Japan
- Prior art keywords
- fragment
- antibody
- seq
- constant region
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims description 102
- 108010056102 CD100 antigen Proteins 0.000 claims description 35
- 102100027744 Semaphorin-4D Human genes 0.000 claims description 32
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 32
- 108091033319 polynucleotide Proteins 0.000 claims description 20
- 102000040430 polynucleotide Human genes 0.000 claims description 20
- 239000002157 polynucleotide Substances 0.000 claims description 20
- 239000000427 antigen Substances 0.000 claims description 13
- 102000036639 antigens Human genes 0.000 claims description 13
- 108091007433 antigens Proteins 0.000 claims description 13
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims description 12
- 208000027866 inflammatory disease Diseases 0.000 claims description 11
- 150000007523 nucleic acids Chemical group 0.000 claims description 11
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 10
- 208000023275 Autoimmune disease Diseases 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 239000013598 vector Substances 0.000 claims description 7
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 6
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 6
- 208000010877 cognitive disease Diseases 0.000 claims description 5
- 230000004770 neurodegeneration Effects 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 4
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 4
- 238000006467 substitution reaction Methods 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 206010003591 Ataxia Diseases 0.000 claims description 3
- 201000010374 Down Syndrome Diseases 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- 101100310048 Mus musculus Sema4d gene Proteins 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 206010003246 arthritis Diseases 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 208000011235 central nervous system lupus Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 102100025218 B-cell differentiation antigen CD72 Human genes 0.000 claims description 2
- 208000028698 Cognitive impairment Diseases 0.000 claims description 2
- 101000934359 Homo sapiens B-cell differentiation antigen CD72 Proteins 0.000 claims description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 2
- 102100034384 Plexin-B1 Human genes 0.000 claims description 2
- 101710100559 Plexin-B1 Proteins 0.000 claims description 2
- 102100034383 Plexin-B2 Human genes 0.000 claims description 2
- 101710100551 Plexin-B2 Proteins 0.000 claims description 2
- 206010044688 Trisomy 21 Diseases 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000003472 neutralizing effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 230000000295 complement effect Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 8
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000282567 Macaca fascicularis Species 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000019771 cognition Effects 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 241001515942 marmosets Species 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023039438A JP7460819B2 (ja) | 2017-05-05 | 2023-03-14 | ヒト抗セマフォリン４ｄ抗体 |
| JP2024044422A JP2024081694A (ja) | 2017-05-05 | 2024-03-21 | ヒト抗セマフォリン４ｄ抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762501981P | 2017-05-05 | 2017-05-05 | |
| US62/501,981 | 2017-05-05 | ||
| PCT/US2018/031263 WO2018204895A1 (en) | 2017-05-05 | 2018-05-04 | Human anti-semaphorin 4d antibody |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023039438A Division JP7460819B2 (ja) | 2017-05-05 | 2023-03-14 | ヒト抗セマフォリン４ｄ抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020518248A JP2020518248A (ja) | 2020-06-25 |
| JP2020518248A5 true JP2020518248A5 (enExample) | 2021-05-13 |
| JP7246320B2 JP7246320B2 (ja) | 2023-03-27 |
Family
ID=64016767
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019560083A Active JP7246320B2 (ja) | 2017-05-05 | 2018-05-04 | ヒト抗セマフォリン４ｄ抗体 |
| JP2023039438A Active JP7460819B2 (ja) | 2017-05-05 | 2023-03-14 | ヒト抗セマフォリン４ｄ抗体 |
| JP2024044422A Pending JP2024081694A (ja) | 2017-05-05 | 2024-03-21 | ヒト抗セマフォリン４ｄ抗体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023039438A Active JP7460819B2 (ja) | 2017-05-05 | 2023-03-14 | ヒト抗セマフォリン４ｄ抗体 |
| JP2024044422A Pending JP2024081694A (ja) | 2017-05-05 | 2024-03-21 | ヒト抗セマフォリン４ｄ抗体 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11427634B2 (enExample) |
| EP (1) | EP3618865A4 (enExample) |
| JP (3) | JP7246320B2 (enExample) |
| KR (1) | KR102680924B1 (enExample) |
| CN (1) | CN110636858B (enExample) |
| AU (2) | AU2018261947B2 (enExample) |
| BR (1) | BR112019023138A2 (enExample) |
| CA (1) | CA3061963A1 (enExample) |
| IL (1) | IL270244B2 (enExample) |
| MX (2) | MX2019013110A (enExample) |
| SG (1) | SG11201909466RA (enExample) |
| WO (1) | WO2018204895A1 (enExample) |
| ZA (1) | ZA201907148B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
| PT3445397T (pt) | 2016-04-22 | 2023-01-13 | Vaccinex Inc | Exibição de proteína integral de membrana sobre viriões envelopados extracelulares de poxvírus |
| SG11201900595YA (en) | 2016-08-02 | 2019-02-27 | Vaccinex Inc | Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells |
| JP7246320B2 (ja) * | 2017-05-05 | 2023-03-27 | バクシネックス インコーポレーティッド | ヒト抗セマフォリン４ｄ抗体 |
| CA3152371A1 (en) | 2019-08-01 | 2021-02-04 | Vaccinex, Inc. | Combined inhibition of semaphorin-4d and tgf.beta. and compositions therefor |
| US11597765B2 (en) | 2020-06-25 | 2023-03-07 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules for the treatment of Rett syndrome |
| MX2024003883A (es) | 2021-09-27 | 2024-08-28 | Vaccinex Inc | Perfil predictivo de resultados para el uso de una molecula de union de antisemaforina-4d para el tratamiento de trastornos neurodegenerativos. |
| US20230331863A1 (en) | 2022-02-13 | 2023-10-19 | Vaccinex, Inc. | Combination therapy with semaphorin-4d blockade and htt-lowering agent for treatment of huntington's disease |
| KR102875105B1 (ko) * | 2023-04-03 | 2025-10-21 | 주식회사 사이알바이오 | 재조합 세마포린 4d 차단항체를 유효성분으로 포함하는 쇼그렌 증후군 예방 또는 치료용 약학 조성물 |
| CN117924494B (zh) * | 2024-01-23 | 2025-02-25 | 首都医科大学附属北京积水潭医院 | 特异性结合sema4d的抗原结合蛋白及其应用 |
| WO2026030311A1 (en) | 2024-07-29 | 2026-02-05 | Vaccinex, Inc. | Use of semaphorin-4d inhibitory molecules to treat cognitive impairment |
| WO2026080818A1 (en) | 2024-10-10 | 2026-04-16 | Vaccinex, Inc. | Use of anti-semaphorin-4d inhibitory molecules in combination with flt3 ligand to inhibit tumor growth and metastasis |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ201918A (en) | 1981-09-18 | 1987-04-30 | Genentech Inc | N-terminal methionyl analogues of bovine growth hormone |
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| GB2183662B (en) | 1985-04-01 | 1989-01-25 | Celltech Ltd | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| WO1989012624A2 (en) | 1988-06-14 | 1989-12-28 | Cetus Corporation | Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| IE63847B1 (en) | 1989-05-05 | 1995-06-14 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| DE69127749T2 (de) | 1990-03-20 | 1998-04-16 | The Trustees Of Columbia University In The City Of New York, New York, N.Y. | Chimäre antikörper mit rezeptor-bindenden liganden anstelle ihrer konstanten region |
| ATE218889T1 (de) | 1990-11-09 | 2002-06-15 | Stephen D Gillies | Cytokine immunokonjugate |
| FR2686087A1 (fr) | 1992-01-13 | 1993-07-16 | Inst Nat Sante Rech Med | Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications. |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US20020102208A1 (en) | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
| CN1306272C (zh) | 2000-11-17 | 2007-03-21 | 罗切斯特大学 | 筛选编码抗原特异性免疫球蛋白分子或其抗原特异性片段的方法 |
| AU2002327164A1 (en) | 2001-01-29 | 2002-12-09 | Idec Pharmaceuticals Corporation | Engineered tetravalent antibodies and methods of use |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| EP1442749A1 (en) | 2003-01-31 | 2004-08-04 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system |
| PT2032606E (pt) | 2006-05-30 | 2014-02-05 | Genentech Inc | Anticorpos e imunoconjugados e respetivas utilizações |
| JP5244785B2 (ja) * | 2006-08-11 | 2013-07-24 | 小野薬品工業株式会社 | ストローマ由来因子−１（ｓｄｆ−１）に対するモノクローナル抗体 |
| WO2008100995A1 (en) | 2007-02-14 | 2008-08-21 | Vaccinex, Inc. | Humanized anti-cd100 antibodies |
| FI20075278A0 (fi) | 2007-04-20 | 2007-04-20 | Biotie Therapies Corp | Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet |
| US20110022149A1 (en) | 2007-06-04 | 2011-01-27 | Cox Brian J | Methods and devices for treatment of vascular defects |
| CN102264763B (zh) | 2008-09-19 | 2016-04-27 | 米迪缪尼有限公司 | 定向于dll4的抗体及其用途 |
| EP2427212B1 (en) | 2009-05-08 | 2017-08-23 | Vaccinex, Inc. | Anti-cd100 antibodies and methods for using the same |
| EP2711023B1 (en) | 2011-05-13 | 2017-07-12 | National University Corporation Tokyo Medical and Dental University | Osteogenesis promoter |
| EA029023B1 (ru) | 2011-10-11 | 2018-01-31 | Вэксинекс, Инк. | Применение молекул, связывающих семафорин-4d, для модуляции проницаемости гематоэнцефалического барьера |
| US9090709B2 (en) | 2012-03-28 | 2015-07-28 | Vaccinex, Inc. | Anti-SEMA4D antibodies and epitopes |
| US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
| US10494440B2 (en) * | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
| US9243068B2 (en) | 2013-06-25 | 2016-01-26 | Vaccinex, Inc. | Combination of SEMA-4D inhibitors and immunomodulators to inhibit tumors and metastases |
| NZ630881A (en) | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
| NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
| CN104127862A (zh) * | 2014-08-14 | 2014-11-05 | 武汉大学 | Semaphorin 4D在预防及治疗骨代谢性疾病中的应用 |
| EP3233915B1 (en) * | 2014-12-15 | 2024-08-28 | MorphoSys AG | Antibodies for il-17c |
| KR102533921B1 (ko) | 2017-02-22 | 2023-05-17 | 백시넥스 인코포레이티드 | 신경변성 또는 신경염증성 질환에서의 신경교세포 활성화의 조기 검출 |
| JP7246320B2 (ja) * | 2017-05-05 | 2023-03-27 | バクシネックス インコーポレーティッド | ヒト抗セマフォリン４ｄ抗体 |
| US11597765B2 (en) * | 2020-06-25 | 2023-03-07 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules for the treatment of Rett syndrome |
-
2018
- 2018-05-04 JP JP2019560083A patent/JP7246320B2/ja active Active
- 2018-05-04 BR BR112019023138-2A patent/BR112019023138A2/pt unknown
- 2018-05-04 AU AU2018261947A patent/AU2018261947B2/en active Active
- 2018-05-04 MX MX2019013110A patent/MX2019013110A/es unknown
- 2018-05-04 CA CA3061963A patent/CA3061963A1/en active Pending
- 2018-05-04 KR KR1020197034009A patent/KR102680924B1/ko active Active
- 2018-05-04 CN CN201880029632.7A patent/CN110636858B/zh active Active
- 2018-05-04 EP EP18793831.1A patent/EP3618865A4/en active Pending
- 2018-05-04 WO PCT/US2018/031263 patent/WO2018204895A1/en not_active Ceased
- 2018-05-04 IL IL270244A patent/IL270244B2/en unknown
- 2018-05-04 SG SG11201909466R patent/SG11201909466RA/en unknown
- 2018-05-04 US US16/611,209 patent/US11427634B2/en active Active
-
2019
- 2019-10-29 ZA ZA2019/07148A patent/ZA201907148B/en unknown
- 2019-11-04 MX MX2023003519A patent/MX2023003519A/es unknown
-
2022
- 2022-07-19 US US17/813,375 patent/US12006365B2/en active Active
-
2023
- 2023-03-14 JP JP2023039438A patent/JP7460819B2/ja active Active
-
2024
- 2024-03-21 JP JP2024044422A patent/JP2024081694A/ja active Pending
- 2024-05-03 US US18/654,538 patent/US12668630B2/en active Active
- 2024-07-10 AU AU2024204752A patent/AU2024204752A1/en active Pending